CSPHF
CStone Pharmaceuticals, a biopharmaceutical company, researches, develops, and commercializes immuno-oncology and precision medicines to address the unmet medical needs of cancer patients in China and internationally. It offers Sugemalimab, a monoclonal antibody against programmed death (PD) ligand 1; GAVRETO, an RET inhibitor for the treatment of patients with advanced or metastatic RET-mutant medullary and RET fusion-positive thyroid cancers; and avapritinib, a KIT/PDGFRA inhibitor to treat adults with unresectable or metastatic gastrointestinal stromal tumors harboring a PDGFRA exon 18 mutation. The company's product pipeline includes Nofazinlimab, a PD-1 antibody for the treatment of patients with hepatocellular carcinoma; Ivosidenib, an isocitrate dehydrogenase 1 (IDH1) inhibitor to treat adults with relapsed or refractory acute myeloid leukemia with an IDH1 mutation; and Fisogatinib, an FGFR4 inhibitor to treat hepatocellular carcinoma. Its products also comprise CS1002, CS2006, CS3002, CS3005, CS2007, CS2008, and CS500 for solid tumors; and CS5001 for solid tumors and hematologic malignancies. The company was incorporated in 2015 and is headquartered in Shanghai, China.
| Period | EPS | Revenue | FCF |
|---|---|---|---|
| 2025 Q4 | -0.11 | $216M | -$56M |
| 2025 Q2 | -0.10 | $25M | -$38M |
| 2024 Q4 | -0.08 | $153M | -$156M |
| 2024 Q2 | 0.01 | $254M | -$187M |
| 2023 Q4 | -0.12 | $202M | -$248M |
| 2023 Q2 | -0.17 | $261M | -$341M |
| 2022 Q4 | -0.46 | $220M | -$166M |
| 2022 Q2 | -0.32 | $262M | -$445M |